Tamsulosin Hydrochloride is an alpha-1A adrenergic blocker indicated for signs and symptoms of benign prostatic hyperplasia. We supply it to US manufacturers of capsules.
Data from PubChem (CID 5362376) and FDA’s substance registry
CAS number
106463-17-6
Molecular formula
C20H29ClN2O5S
Molecular weight
445.0g/mol
FDA UNII
IUPAC name
5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide;hydrochloride
InChIKey
ZZIZZTHXZRDOFM-XFULWGLBSA-N
- Appearance
- White or almost white crystalline powder that melts with decomposition at about 230 °C.
- Solubility
- Sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
A low-dose, potent API: one capsule holds 0.4 mg. It is the single R-enantiomer, so check the limit for the S-enantiomer and ask how the source handles containment.
On the US market
- Reference product
- FlomaxNDA 020579
- Approved ANDAs
- 11 with a marketed product
- Approved forms and strengths
- Capsule 0.4 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com